Redx Pharma appoints Sarah Gordon as non-executive Director


Gordon has been appointed due to deep experience of the biotechnology industry and capital markets

Redx Pharma, the drug discovery and development company focused on cancer and fibrosis, has appointed Sarah Gordon Wild as an Independent non-Executive Director, with effect from 1 July 2020.

Gordon brings extensive investment experience in the biotechnology sector to her role at Redx. She currently also serves as a Non-Executive Director of Oxford Nanopore Technologies and Evox Therapeutics, as well as being a Board Member of Lone Pine Capital's Offshore Funds.

Between 1998-2003 Sarah was Managing Director, Management Committee Member and Senior Healthcare Analyst at Lone Pine Capital. Before this, for over 15 years, Sarah was a senior biotechnology/healthcare analyst on Wall Street at firms including; Amerindo Investments Advisors, Hambrecht & Quist, Kleinwort Grieveson, and Greig Middleton.

Gordon graduated from Aberdeen University with a BSc (Hons) in Zoology and with an MSc from Imperial College, London in Social & Economic Aspects of Science and Technology in Industry.

Iain Ross, Chairman of the Board of Redx said: "We are delighted to welcome Sarah to the Board. I am confident that Redx will benefit from her counsel and deep understanding of the biotechnology sector and capital markets as we seek to build a leading biotech company focused on novel medicines that have the potential to transform the treatment of oncology and fibrosis."

Sign up for your free email newsletter

Sarah Gordon Wild added: "I am excited to be joining the Board as a non-executive director. Over a relatively short space of time, Redx has established a strong track record as a medicinal chemistry team and now has focused on a few very exciting programmes, as well as a strong management team. I look forward to seeing this pipeline progress in my Board role."